Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Indian Journal of Gastroenterology
Erschienen in: Indian Journal of Gastroenterology 6/2018

18.12.2018 | Review Article

Hepatitis C virus infection and chronic renal disease: A review

verfasst von: Amit Goel, Dharmendra Singh Bhadauria, Rakesh Aggarwal

Erschienen in: Indian Journal of Gastroenterology | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Hepatitis C virus (HCV) is a parenterally-transmitted hepatotropic virus that often causes chronic infection, which can progress to cirrhosis and hepatocellular carcinoma. Development of highly effective direct-acting anti-viral agents (DAAs) has led to a paradigm change in the treatment of HCV infection over the last 4–5 years. Patients with chronic kidney disease (CKD) are at a higher risk of acquiring HCV infection. In these patients, diagnosis of HCV infection, assessment of the consequent liver disease and management of HCV infection pose some specific problems. This article reviews the available recent information on HCV infection and CKD, including the association between these conditions and their effect on each other, and prevention, evaluation, and management of HCV infection in persons with CKD. This review looks at this issue particularly from the perspective of readers in Asia, especially India, since the epidemiology of HCV-CKD association and the repertoire of anti-HCV drugs available in this region differ from those elsewhere.
Literatur
1.
Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359–62.CrossRefPubMed
2.
3.
KDIGO. KDIGO 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl. 2018;8:91–165.CrossRef
4.
Levey AS, Coresh J, Greene T, et al. Chronic kidney disease epidemiology collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–54.CrossRefPubMed
5.
Welzel TM, Petersen J, Herzer K, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut. 2016;65:1861–70.CrossRefPubMed
6.
Goel A, Bhargava R, Rai P, Aggarwal R. Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: an Indian experience. Indian J Gastroenterol. 2017;36:227–34.CrossRefPubMed
7.
Goel A, Bhadauria DS, Kaul A, et al. Experience with direct acting anti-viral agents for treating hepatitis C virus infection in renal transplant recipients. Indian J Gastroenterol. 2017;36:137–40.CrossRefPubMed
8.
Taneja S, Duseja A, De A, et al. Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients. Nephrology (Carlton). 2018;23:876–82.CrossRef
9.
10.
Fabrizi F, Marcelli D, Bacchini G, Guarnori I, Erba G, Locatelli F. Antibodies to hepatitis C virus (HCV) in chronic renal failure (CRF) patients on conservative therapy: prevalence, risk factors and relationship to liver disease. Nephrol Dial Transplant. 1994;9:780–4.PubMed
11.
Garcia-Valdecasas J, Bernal C, Garcia F, et al. Epidemiology of hepatitis C virus infection in patients with renal disease. J Am Soc Nephrol. 1994;5:186–92.PubMed
12.
Sit D, Kadiroglu AK, Kayabasi H, Yilmaz ME, Goral V. Seroprevalence of hepatitis B and C viruses in patients with chronic kidney disease in the predialysis stage at a university hospital in Turkey. Intervirology. 2007;50:133–7.CrossRefPubMed
13.
Lemos LB, Perez RM, Lemos MM, et al. Hepatitis C among predialysis patients: prevalence and characteristics in a large cohort of patients. Nephron Clin Pract. 2008;108:c135–40.CrossRefPubMed
14.
15.
Li Cavoli G, Ferrantelli A, Bono L, et al. Incidence of hepatitis C virus infection in patients with chronic kidney disease on conservative therapy. Int J Infect Dis. 2011;15:e514–6.CrossRefPubMed
16.
Rahnavardi M, Hosseini Moghaddam SM, Alavian SM. Hepatitis C in hemodialysis patients: current global magnitude, natural history, diagnostic difficulties, and preventive measures. Am J Nephrol. 2008;28:628–40.CrossRefPubMed
17.
Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl. 2008;73suppl 109:S1–99.
18.
Johnson DW, Dent H, Yao Q, et al. Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data. Nephrol Dial Transplant. 2009;24:1598–603.CrossRefPubMed
19.
Su Y, Norris JL, Zang C, Peng Z, Wang N. Incidence of hepatitis C virus infection in patients on hemodialysis: a systematic review and meta-analysis. Hemodial Int. 2013;17:532–41.PubMed
20.
Fissell RB, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2004;65:2335–42.CrossRefPubMed
21.
Fabrizi F, Messa P, Martin P. Transmission of hepatitis C virus infection in hemodialysis: current concepts. Int J Artif Organs. 2008;31:1004–16.CrossRefPubMed
22.
23.
Caramelo C, de Sequera P, Lopez MD, Ortiz A. Hand-borne mechanisms of dissemination of hepatitis C virus in dialysis units: basis for new addenda to the present preventive strategies. Clin Nephrol. 1999;51:59–60.PubMed
24.
Samandari T, Malakmadze N, Balter S, et al. A large outbreak of hepatitis B virus infections associated with frequent injections at a physician's office. Infect Control Hosp Epidemiol. 2005;26:745–50.CrossRefPubMed
25.
Bender TJ, Wise ME, Utah O, et al. Outbreak of hepatitis B virus infections associated with assisted monitoring of blood glucose in an assisted living facility-Virginia, 2010. PLoS One. 2012;7:e50012.CrossRefPubMedPubMedCentral
26.
Patel PR, Thompson ND, Kallen AJ, Arduino MJ. Epidemiology, surveillance, and prevention of hepatitis C virus infections in hemodialysis patients. Am J Kidney Dis. 2010;56:371–8.CrossRefPubMed
27.
Girou E, Chevaliez S, Challine D, et al. Determinant roles of environmental contamination and noncompliance with standard precautions in the risk of hepatitis C virus transmission in a hemodialysis unit. Clin Infect Dis. 2008;47:627–33.CrossRefPubMed
28.
Caramelo C, Navas S, Alberola ML, Bermejillo T, Reyero A, Carreno V. Evidence against transmission of hepatitis C virus through hemodialysis ultrafiltrate and peritoneal fluid. Nephron. 1994;66:470–3.CrossRefPubMed
29.
dos Santos JP, Loureiro A, Cendoroglo Neto M, Pereira BJ. Impact of dialysis room and reuse strategies on the incidence of hepatitis C virus infection in haemodialysis units. Nephrol Dial Transplant. 1996;11:2017–22.CrossRefPubMed
30.
Jadoul M, Poignet JL, Geddes C, et al. The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study. Nephrol Dial Transplant. 2004;19:904–9.CrossRefPubMed
31.
Thompson ND, Novak RT, Datta D, et al. Hepatitis C virus transmission in hemodialysis units: importance of infection control practices and aseptic technique. Infect Control Hosp Epidemiol. 2009;30:900–3.CrossRefPubMed
32.
Izopet J, Pasquier C, Sandres K, Puel J, Rostaing L. Molecular evidence for nosocomial transmission of hepatitis C virus in a French hemodialysis unit. J Med Virol. 1999;58:139–44.CrossRefPubMed
33.
Jadoul M, Cornu C, van Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian multicenter study. The Universitaires Cliniques St-Luc (UCL) collaborative group. Kidney Int. 1998;53:1022–5.CrossRefPubMed
34.
Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep. 2001;50:1–43.
35.
Bravo Zuniga JI, Loza Munarriz C, Lopez-Alcalde J. Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis units. Cochrane Database Syst Rev. 2016:CD006420.
36.
Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36:S35–46.PubMed
37.
38.
Furusyo N, Hayashi J, Kakuda K, et al. Acute hepatitis C among Japanese hemodialysis patients: a prospective 9-year study. Am J Gastroenterol. 2001;96:1592–600.CrossRefPubMed
39.
Espinosa M, Martin-Malo A, Alvarez de Lara MA, Gonzalez R, Rodriguez M, Aljama P. Natural history of acute HCV infection in hemodialysis patients. Clin Nephrol. 2002;58:143–50.CrossRefPubMed
40.
Hu KQ, Lee SM, Hu SX, Xia VW, Hillebrand DJ, Kyulo NL. Clinical presentation of chronic hepatitis C in patients with end-stage renal disease and on hemodialysis versus those with normal renal function. Am J Gastroenterol. 2005;100:2010–8.CrossRefPubMed
41.
Martin P, Carter D, Fabrizi F, et al. Histopathological features of hepatitis C in renal transplant candidates. Transplantation. 2000;69:1479–84.CrossRefPubMed
42.
Liu CH, Liang CC, Huang KW, et al. Transient elastography to assess hepatic fibrosis in hemodialysis chronic hepatitis C patients. Clin J Am Soc Nephrol. 2011;6:1057–65.CrossRefPubMedPubMedCentral
43.
Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta-analysis: effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther. 2004;20:1271–7.CrossRefPubMed
44.
Fabrizi F, Takkouche B, Lunghi G, Dixit V, Messa P, Martin P. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat. 2007;14:697–703.PubMed
45.
Goodkin DA, Bieber B, Jadoul M, Martin P, Kanda E, Pisoni RL. Mortality, hospitalization, and quality of life among patients with hepatitis C infection on hemodialysis. Clin J Am Soc Nephrol. 2017;12:287–97.CrossRefPubMed
46.
Chou CY, Wang IK, Liu JH, Lin HH, Wang SM, Huang CC. Comparing survival between peritoneal dialysis and hemodialysis treatment in ESRD patients with chronic hepatitis C infection. Perit Dial Int. 2010;30:86–90.PubMed
47.
Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med. 1993;328:465–70.CrossRefPubMed
48.
Davda R, Peterson J, Weiner R, Croker B, Lau JY. Membranous glomerulonephritis in association with hepatitis C virus infection. Am J Kidney Dis. 1993;22:452–5.CrossRefPubMed
49.
Okada K, Takishita Y, Shimomura H, et al. Detection of hepatitis C virus core protein in the glomeruli of patients with membranous glomerulonephritis. Clin Nephrol. 1996;45:71–6.PubMed
50.
Moe SM, Pampalone AJ, Ofner S, Rosenman M, Teal E, Hui SL. Association of hepatitis C virus infection with prevalence and development of kidney disease. Am J Kidney Dis. 2008;51:885–92.CrossRefPubMedPubMedCentral
51.
Lai TS, Lee MH, Yang HI, et al. High hepatitis C viral load and genotype 2 are strong predictors of chronic kidney disease. Kidney Int. 2017;92:703–9.CrossRefPubMed
52.
Kurbanova N, Qayyum R. Association of hepatitis C virus infection with proteinuria and glomerular filtration rate. Clin Transl Sci. 2015;8:421–4.CrossRefPubMedPubMedCentral
53.
Fabrizi F, Verdesca S, Messa P, Martin P. Hepatitis C virus infection increases the risk of developing chronic kidney disease: a systematic review and meta-analysis. Dig Dis Sci. 2015;60:3801–13.CrossRefPubMed
54.
Fabrizi F, Donato FM, Messa P. Association between hepatitis C virus and chronic kidney disease: a systematic review and meta-analysis. Ann Hepatol. 2018;17:364–91.CrossRefPubMed
55.
Lai TS, Lee MH, Yang HI, et al. Hepatitis C viral load, genotype, and increased risk of developing end-stage renal disease: REVEAL-HCV study. Hepatology. 2017;66:784–93.CrossRefPubMed
56.
Daghestani L, Pomeroy C. Renal manifestations of hepatitis C infection. Am J Med. 1999;106:347–54.CrossRefPubMed
57.
Ishizaka N, Ishizaka Y, Takahashi E, et al. Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. Lancet. 2002;359:133–5.CrossRefPubMed
58.
Alavian SM, Taheri S. Inauspicious contribution of hepatitis C virus and diabetes mellitus targeting kidneys: an update. Iran J Kidney Dis. 2012;6:236–54.PubMed
59.
Sise ME, Backman E, Ortiz GA, et al. Effect of sofosbuvir-based hepatitis C virus therapy on kidney function in patients with CKD. Clin J Am Soc Nephrol. 2017;12:1615–23.CrossRefPubMedPubMedCentral
60.
61.
Lakshmi V, Reddy AK, Dakshinamurty KV. Evaluation of commercially available third-generation anti-hepatitis C virus enzyme-linked immunosorbent assay in patients on haemodialysis. Indian J Med Microbiol. 2007;25:140–2.CrossRefPubMed
62.
Kalantar-Zadeh K, Miller LG, Daar ES. Diagnostic discordance for hepatitis C virus infection in hemodialysis patients. Am J Kidney Dis. 2005;46:290–300.CrossRefPubMed
63.
Freiman JM, Tran TM, Schumacher SG, et al. Hepatitis C core antigen testing for diagnosis of hepatitis C virus infection: a systematic review and meta-analysis. Ann Intern Med. 2016;165:345–55.CrossRefPubMedPubMedCentral
64.
Trevizoli JE, de Paula MR, Ribeiro Velasco LF, et al. Hepatitis C is less aggressive in hemodialysis patients than in nonuremic patients. Clin J Am Soc Nephrol. 2008;3:1385–90.CrossRefPubMedPubMedCentral
65.
Saab S, Martin P, Brezina M, Gitnick G, Yee HF Jr. Serum alanine aminotransferase in hepatitis C screening of patients on hemodialysis. Am J Kidney Dis. 2001;37:308–15.CrossRefPubMed
66.
67.
Pawlotsky JM. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology. 2016;151:70–86.CrossRefPubMed
68.
Nookathota M, Mukherjee S. Antiviral therapy for chronic hepatitis C in 2014. Expert Rev Clin Pharmacol. 2014;7:499–505.CrossRefPubMed
69.
Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis. 2016;62:683–94.CrossRefPubMedPubMedCentral
70.
71.
EASL. Recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69:461–511.CrossRef
72.
Gane EJ, Robson RA, Bonacini M, et al. Anti-viral efficacy and pharmacokinetics (PK) of sofosbuvir (SOF) in patients with severe renal impairment. Hepatology. 2014;60:667A.
73.
Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386:1537–45.CrossRefPubMed
74.
Gane E, Lawitz E, Pugatch D, et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med. 2017;377:1448–55.CrossRefPubMed
75.
Goel A, Bhadauria DS, Kaul A, et al. Daclatasvir and reduced-dose sofosbuvir: an effective and pangenotypic treatment for hepatitis C in patients with eGFR <30 ml/min. Nephrology (Carlton). 2018: (in press). doi: https://​doi.​org/​10.​1111/​nep.​13222.
76.
He YL, Yang SJ, Hu CH, et al. Safety and efficacy of sofosbuvir-based treatment of acute hepatitis C in end-stage renal disease patients undergoing haemodialysis. Aliment Pharmacol Ther. 2018;47:526–32.CrossRefPubMed
77.
Taneja S, Duseja A, De A, et al. Low-dose Sofosbuvir is safe and effective in treating chronic hepatitis C in patients with severe renal impairment or end-stage renal disease. Dig Dis Sci. 2018;63:1334–40.CrossRefPubMed
78.
Goel A, Chen Q, Chhatwal J, Aggarwal R. Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment. J Gastroenterol Hepatol. 2018; (in press). https://​doi.​org/​10.​1111/​jgh.​14301.
79.
Prasad N, Patel MR, Pandey A, et al. Direct-acting antiviral agents in hepatitis C virus-infected renal allograft recipients: treatment and outcome experience from single center. Indian J Nephrol. 2018;28:220–5.CrossRefPubMedPubMedCentral
80.
Kamar N, Marion O, Rostaing L, et al. Efficacy and safety of Sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation. Am J Transplant. 2016;16:1474–9.CrossRefPubMed
81.
Sise ME, Chute DF, Gustafson JL, et al. Transplantation of hepatitis C virus infected kidneys into hepatitis C virus uninfected recipients. Hemodial Int. 2018;22Suppl 1:S71–80.
82.
Scalea JR, Barth RN, Munivenkatappa R, et al. Shorter waitlist times and improved graft survivals are observed in patients who accept hepatitis C virus+ renal allografts. Transplantation. 2015;99:1192–6.CrossRefPubMed
83.
Goldberg DS, Abt PL, Blumberg EA, et al. Trial of transplantation of HCV-infected kidneys into uninfected recipients. N Engl J Med. 2017;376:2394–5.CrossRefPubMed
84.
Durand CM, Bowring MG, Brown DM, et al. Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: an open-label nonrandomized trial. Ann Intern Med. 2018;168:533–40.CrossRefPubMedPubMedCentral
85.
Campos-Varela I, Agudelo EZ, Sarkar M, Roberts JP, Terrault NA. Use of a hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA-negative liver transplant recipient. Transpl Infect Dis. 2018;20: (in press). https://​doi.​org/​10.​1111/​tid.​12809.
86.
Coilly A, Samuel D. Pros and cons: usage of organs from donors infected with hepatitis C virus—revision in the direct-acting antiviral era. J Hepatol. 2016;64:226–31.CrossRefPubMed
87.
Trotter PB, Summers DM, Ushiro-Lumb I, et al. Use of organs from hepatitis C virus-positive donors for uninfected recipients: a potential cost-effective approach to save lives? Transplantation. 2018;102:664–72.CrossRefPubMed
88.
Chhatwal J, Kanwal F. Cost-effectiveness and decision analysis in clinical gastroenterology and hepatology: from evidence to informed decision making. Clin Gastroenterol Hepatol. 2018;16:459–61.CrossRefPubMed
89.
Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med. 2015;162:397–406.CrossRefPubMedPubMedCentral
90.
Aggarwal R, Chen Q, Goel A, et al. Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India. PLoS One. 2017;12:e0176503.CrossRefPubMedPubMedCentral
91.
Bethea ED, Chen Q, Hur C, Chung RT, Chhatwal J. Should we treat acute hepatitis C? A decision and cost-effectiveness analysis. Hepatology. 2018;67:837–46.CrossRefPubMed
92.
Elbasha E, Greaves W, Roth D, Nwankwo C. Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States. J Viral Hepat. 2017;24:268–79.CrossRefPubMed
93.
Shelton BA, Sawinski D, Linas BP, et al. Population level outcomes and cost-effectiveness of hepatitis C treatment pre- vs postkidney transplantation. Am J Transplant. 2018;18:2483–95.CrossRefPubMedPubMedCentral
Metadaten
Titel
Hepatitis C virus infection and chronic renal disease: A review
verfasst von
Amit Goel
Dharmendra Singh Bhadauria
Rakesh Aggarwal
Publikationsdatum
18.12.2018
Verlag
Springer India
Erschienen in
Indian Journal of Gastroenterology / Ausgabe 6/2018
Print ISSN: 0254-8860
Elektronische ISSN: 0975-0711
DOI
https://doi.org/10.1007/s12664-018-0920-3

Weitere Artikel der Ausgabe 6/2018

Indian Journal of Gastroenterology 6/2018 Zur Ausgabe

Original Article

Comparative study of intestinal malrotation in infant, children, and adult in a tertiary care center in India

Letter

Intermittent or continuous infusion of terlipressin for acute variceal bleeding—“cherry picking” to make it simpler

Image

Esophageal Abrikossoff tumor

Original Article

Indian consensus on chronic constipation in adults: A joint position statement of the Indian Motility and Functional Diseases Association and the Indian Society of Gastroenterology

Editorial

Chronic constipation, more needs to be done

Short report

Multiple rapid swallow testing in patients with gastroesophageal reflux disease

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Metformin rückt in den Hintergrund

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

24.04.2024 | DGIM 2024 | Nachrichten

Bei Senioren mit Prostatakarzinom auf Anämie achten!
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise